ClinicalTrials.gg
CompletedNCT03922542Updated Sep 17, 2026

Comparison of Standard vs. Accelerated Corneal Crosslinking

A Phase 2/3 interventional study of riboflavin 0.1% and Riboflavin 0.1% in Keratoconus and Ectasia Corneal, sponsored by Price Vision Group. Completed at 1 site in United States. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Price Vision Group · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
508
Allocation
Randomized
Ages
10 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing riboflavin in Keratoconus — 5 open to participants now, 8 under way, 7 of them phase 3. Riboflavin · Keratoconus.

Enrollment
4th of 23
508 · median 170
Started
2019
the only one that year
Phase 2/3
4 of 23
1 open now
Registered
18th of 23
by date
Lead sponsor
3 of 23
Price Vision Group

Among the 23 studies testing riboflavin in Keratoconus, this one is the 4th largest by enrollment, is the only one that started in 2019, is one of 4 in phase 2/3, and was the 18th registered.

Keratoconus

313 studies on the registry are indexed under Keratoconus; 56 are open to participants now.

Browse Keratoconus studies →

Open to participants now

5 of the 23 studies testing riboflavin in Keratoconus are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About riboflavin

Riboflavin: first FDA approval 1953 (M.V.I.-12 ADULT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Keratoconus studies recruiting now, 21 (57%) set no upper age limit and 11 (30%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.

This study: 10 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing riboflavin in Keratoconus, or all of them as a file.
02

Study summary

The study objective is to compare accelerated and standard corneal crosslinking for treatment of progressive keratoconus or corneal ectasia.

03

Conditions studied

  • Keratoconus
  • Ectasia Corneal

Browse trials for

04

Who can participate

Ages eligible
10 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented keratoconus or ectasia after refractive surgery

Exclusion criteria

Exclusion Criteria:

  • Insufficient corneal thickness
  • Ocular condition that may predispose the eye to complications
  • History of chemical injury or delayed epithelial healing
  • Condition that would interfere with or prolong epithelial healing
  • Known sensitivity to treatment medications
  • Pregnancy
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
508 participants (actual)

Study arms

  • Active comparator
    Accelerated

    Treatment with 0.1% riboflavin eye drops and 9 mW/cm2 UVA light for 10 minutes

    Combination Product: riboflavin 0.1%

  • Active comparator
    Standard

    Treatment with 0.1% riboflavin eye drops and 3 mW/cm2 UVA light for 30 minutes

    Combination Product: Riboflavin 0.1%

Interventions

  • Combination productriboflavin 0.1%

    Use of riboflavin 0.1% eye drops and 9 mW/cm2 UVA light for 10 minutes

  • Combination productRiboflavin 0.1%

    Use of riboflavin 0.1% eye drops and 3 mW/cm2 UVA light for 30 minutes

06

What researchers measure

Primary outcomes

  1. Change in maximum keratometry

    assessed by corneal tomography

    Time frame: 6 months

Secondary outcomes

  1. Change in corrected distance visual acuity

    assessed with Snellen chart

    Time frame: 6 months

  2. Change in uncorrected distance visual acuity

    assessed with Snellen chart

    Time frame: 6 months

07

Study locations

1 site
  • Price Vision Group
    Indianapolis, Indiana 46260, United States
08

References and documents

Publications

  • Price MO, Fairchild K, Feng MT, Price FW Jr. Prospective Randomized Trial of Corneal Cross-linking Riboflavin Dosing Frequencies for Treatment of Keratoconus and Corneal Ectasia. Ophthalmology. 2018 Apr;125(4):505-511. doi: 10.1016/j.ophtha.2017.10.034. Epub 2017 Dec 2. PubMed 29203068 ↗
  • Lautert J, Doshi D, Price FW Jr, Price MO. Corneal Epithelial Remodeling After Standard Epithelium-off Corneal Cross-linking in Keratoconic Eyes. J Refract Surg. 2018 Jun 1;34(6):408-412. doi: 10.3928/1081597X-20180402-03. PubMed 29889294 ↗
  • Price MO, Feng MT, Price FW Jr. Patient satisfaction with epithelium-off corneal crosslinking. J Cataract Refract Surg. 2018 Mar;44(3):323-328. doi: 10.1016/j.jcrs.2017.12.023. Epub 2018 Mar 28. PubMed 29605283 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Jun 2026, 86 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2019
First posted
Apr 22, 2019
StartActual
Apr 16, 2019
Primary completionActual
Jun 30, 2026
CompletionActual
Jun 30, 2026
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03922542
Lead sponsor
Price Vision Group
Responsible party
Sponsor
First posted
Apr 22, 2019
Start date
Apr 16, 2019
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026
Last update
Sep 17, 2026

Study contacts

Francis W Price, Jr., MD
principal investigator · Price Vision Group

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Riboflavin

Start the discussion